title: Incentive learning underlying cocaine-seeking requires mGluR5 receptors located on dopamine D1 receptor-expressing neurons.
abstract: Understanding the psychobiological basis of relapse remains a challenge in developing therapies for drug addiction. Relapse in cocaine addiction often occurs following exposure to environmental stimuli previously associated with drug taking. The metabotropic glutamate receptor, mGluR5, is potentially important in this respect; it plays a central role in several forms of striatal synaptic plasticity proposed to underpin associative learning and memory processes that enable drug-paired stimuli to acquire incentive motivational properties and trigger relapse. Using cell type-specific RNA interference, we have generated a novel mouse line with a selective knock-down of mGluR5 in dopamine D1 receptor-expressing neurons. Although mutant mice self-administer cocaine, we show that reinstatement of cocaine-seeking induced by a cocaine-paired stimulus is impaired. By examining different aspects of associative learning in the mutant mice, we identify deficits in specific incentive learning processes that enable a reward-paired stimulus to directly reinforce behavior and to become attractive, thus eliciting approach toward it. Our findings show that glutamate signaling through mGluR5 located on dopamine D1 receptor-expressing neurons is necessary for incentive learning processes that contribute to cue-induced reinstatement of cocaine-seeking and which may underpin relapse in drug addiction.
authors.affiliation: Molecular Biology of the Cell I, German Cancer Research Center, Heidelberg, Germany.
authors.forename: Martin
authors.initials: M
authors.lastname: Novak
authors.forename: Briac
authors.initials: B
authors.lastname: Halbout
authors.forename: Eoin C
authors.initials: EC
authors.lastname: O'Connor
authors.forename: Jan
authors.initials: J
authors.lastname: Rodriguez Parkitna
authors.forename: Tian
authors.initials: T
authors.lastname: Su
authors.forename: Minqiang
authors.initials: M
authors.lastname: Chai
authors.forename: Hans S
authors.initials: HS
authors.lastname: Crombag
authors.forename: Ainhoa
authors.initials: A
authors.lastname: Bilbao
authors.forename: Rainer
authors.initials: R
authors.lastname: Spanagel
authors.forename: David N
authors.initials: DN
authors.lastname: Stephens
authors.forename: Günther
authors.initials: G
authors.lastname: Schütz
authors.forename: David
authors.initials: D
authors.lastname: Engblom
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D001245:Association Learning / Q000187:drug effects*; D001522:Behavior, Animal; D001921:Brain / Q000166:cytology*; D003042:Cocaine / Q000008:administration & dosage; D019970:Cocaine-Related Disorders / Q000378:metabolism / Q000503:physiopathology / Q000523:psychology; D003214:Conditioning, Classical / Q000187:drug effects / Q000502:physiology; D003216:Conditioning, Operant / Q000187:drug effects / Q000502:physiology; D003463:Cues; D018765:Dopamine Uptake Inhibitors / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D049452:Green Fluorescent Proteins / Q000235:genetics; D051379:Mice; D008822:Mice, Transgenic; D009042:Motivation / Q000187:drug effects / Q000502:physiology*; D009474:Neurons / Q000187:drug effects / Q000502:physiology*; D034622:RNA Interference / Q000502:physiology; D064529:Receptor, Metabotropic Glutamate 5; D017447:Receptors, Dopamine D1 / Q000378:metabolism*; D018080:Receptors, GABA-B / Q000378:metabolism; D018094:Receptors, Metabotropic Glutamate / Q000235:genetics / Q000378:metabolism*; D012054:Reinforcement, Psychology; D012646:Self Administration / Q000379:methods
chemical_list: D018765:Dopamine Uptake Inhibitors; C578936:Grm5 protein, mouse; D064529:Receptor, Metabotropic Glutamate 5; D017447:Receptors, Dopamine D1; D018080:Receptors, GABA-B; D018094:Receptors, Metabotropic Glutamate; D049452:Green Fluorescent Proteins; D003042:Cocaine
references.citation: Eur J Neurosci. 1998 Jun;10(6):1937-45
references.pmid: 9753080
references.citation: Methods Mol Biol. 2009;530:325-42
references.pmid: 19266340
references.citation: Nat Neurosci. 2009 Feb;12(2):182-9
references.pmid: 19136971
references.citation: Nat Rev Neurosci. 2007 Nov;8(11):844-58
references.pmid: 17948030
references.citation: Brain Res Brain Res Rev. 1993 Sep-Dec;18(3):247-91
references.pmid: 8401595
references.citation: Psychopharmacology (Berl). 2004 Nov;176(3-4):459-65
references.pmid: 15138757
references.citation: Science. 1990 Dec 7;250(4986):1429-32
references.pmid: 2147780
references.citation: Neuron. 2000 Mar;25(3):515-32
references.pmid: 10774721
references.citation: Nat Neurosci. 2009 Aug;12(8):1036-41
references.pmid: 19597494
references.citation: Neuron. 2004 Sep 30;44(1):5-21
references.pmid: 15450156
references.citation: Neuropsychopharmacology. 2006 Apr;31(4):778-86
references.pmid: 16123768
references.citation: J Pharmacol Exp Ther. 2009 Jun;329(3):1084-90
references.pmid: 19258516
references.citation: Brain Res Brain Res Rev. 2001 Oct;36(2-3):129-38
references.pmid: 11690609
references.citation: Curr Drug Abuse Rev. 2009 Jan;2(1):83-98
references.pmid: 19630739
references.citation: J Neurosci. 2007 Jul 25;27(30):7921-8
references.pmid: 17652583
references.citation: Mol Psychiatry. 2010 Oct;15(10):987-95
references.pmid: 20125089
references.citation: Neuropharmacology. 2008 Apr;54(5):837-44
references.pmid: 18272187
references.citation: J Neurosci. 1999 Mar 15;19(6):2401-11
references.pmid: 10066290
references.citation: Cell. 2008 Nov 14;135(4):738-48
references.pmid: 19013281
references.citation: Neuropharmacology. 2003 Jan;44(1):8-16
references.pmid: 12559117
references.citation: J Neurosci. 2005 Apr 13;25(15):3763-73
references.pmid: 15829628
references.citation: Psychopharmacology (Berl). 1998 Dec;140(3):331-44
references.pmid: 9877013
references.citation: Neuropharmacology. 2009 Mar;56(4):735-40
references.pmid: 19705571
references.citation: J Neurosci. 2003 Feb 1;23(3):1041-8
references.pmid: 12574434
references.citation: Psychopharmacology (Berl). 2003 Jul;168(1-2):3-20
references.pmid: 12402102
references.citation: Psychol Rev. 1984 Apr;91(2):251-68
references.pmid: 6571424
references.citation: Neuropsychopharmacology. 2010 Jul;35(8):1807-17
references.pmid: 20375996
references.citation: Annu Rev Neurosci. 2006;29:565-98
references.pmid: 16776597
references.citation: Neuropsychopharmacology. 2009 Mar;34(4):820-33
references.pmid: 18800068
references.citation: Neuropharmacology. 2008 Sep;55(4):546-54
references.pmid: 18619984
references.citation: Psychol Rev. 1990 Apr;97(2):147-68
references.pmid: 2186423
references.citation: Proc Natl Acad Sci U S A. 2005 Apr 26;102(17):6189-94
references.pmid: 15833811
references.citation: Philos Trans R Soc Lond B Biol Sci. 2008 Oct 12;363(1507):3169-79
references.pmid: 18640918
references.citation: Psychopharmacology (Berl). 1996 Jun;125(4):371-8
references.pmid: 8826542
references.citation: Neuroscience. 2001;106(3):579-87
references.pmid: 11591458
references.citation: J Neurophysiol. 2001 Nov;86(5):2405-12
references.pmid: 11698530
references.citation: Eur J Pharmacol. 2009 Apr 1;607(1-3):114-20
references.pmid: 19326478
references.citation: Br J Pharmacol. 2008 May;154(2):327-42
references.pmid: 18345022
references.citation: Behav Brain Res. 2009 Sep 14;202(2):238-44
references.pmid: 19463707
references.citation: Neuropharmacology. 2005;49 Suppl 1:167-78
references.pmid: 16023685
references.citation: Biol Psychiatry. 2009 May 15;65(10):869-73
references.pmid: 18930184
references.citation: Nat Neurosci. 2006 Jul;9(7):868-9
references.pmid: 16732275
references.citation: J Neurosci. 2004 Aug 4;24(31):6939-45
references.pmid: 15295029
references.citation: Psychopharmacology (Berl). 1995 Feb;117(3):262-6
references.pmid: 7770601
references.citation: Psychopharmacology (Berl). 2007 Jul;192(4):571-80
references.pmid: 17347848
references.citation: Mol Ther. 2009 Jan;17(1):169-75
references.pmid: 19002161
references.citation: Neurosci Lett. 2006 Feb 20;394(3):246-51
references.pmid: 16300895
references.citation: Eur J Pharmacol. 2004 Sep 19;499(1-2):121-33
references.pmid: 15363959
references.citation: Addict Biol. 2010 Apr;15(2):145-68
references.pmid: 20148777
references.citation: J Neurosci. 2008 May 28;28(22):5671-85
references.pmid: 18509028
references.citation: J Neurosci. 2001 Dec 1;21(23):9471-7
references.pmid: 11717381
references.citation: Trends Neurosci. 2009 Oct;32(10):538-47
references.pmid: 19765834
references.citation: Genes Dev. 2006 Jan 15;20(2):147-52
references.pmid: 16418481
references.citation: Brain Res. 1998 Jan 12;780(2):210-7
references.pmid: 9507137
references.citation: Mol Pharmacol. 2002 Sep;62(3):473-84
references.pmid: 12181423
references.citation: Am Psychol. 1988 Mar;43(3):151-60
references.pmid: 3364852
references.citation: Addict Biol. 2006 Mar;11(1):2-38
references.pmid: 16759333
references.citation: J Neurosci. 2005 Jul 13;25(28):6651-7
references.pmid: 16014726
references.citation: Nat Neurosci. 2001 Sep;4(9):873-4
references.pmid: 11528416
references.citation: Nat Neurosci. 2005 Nov;8(11):1481-9
references.pmid: 16251991
references.citation: Behav Neurosci. 2000 Feb;114(1):42-63
references.pmid: 10718261
references.citation: Nat Neurosci. 2004 Apr;7(4):389-97
references.pmid: 15034590
references.citation: Pharmacol Ther. 2005 Jun;106(3):389-403
references.pmid: 15922019
references.citation: J Neurosci. 2003 Oct 22;23(29):9500-7
references.pmid: 14573529
references.citation: Learn Mem. 2008 Apr 25;15(5):299-303
references.pmid: 18441288
references.citation: Brain Res Rev. 2008 Jun;58(1):121-35
references.pmid: 18234349
references.citation: Trends Neurosci. 2008 Nov;31(11):552-8
references.pmid: 18786735
references.citation: Cell Mol Life Sci. 2008 Sep;65(18):2913-23
references.pmid: 18712277
references.citation: Proc Natl Acad Sci U S A. 2005 Jan 11;102(2):491-6
references.pmid: 15608059
references.citation: Nature. 2006 May 25;441(7092):537-41
references.pmid: 16724069